Life-science briefing: Tuesday, April 1, 2008
TODAY’S HEADLINES:
Oxford NanoLabs takes in £10M for sequencing tech (PDF release)
Alure Medical raises $4.5M for plastic-surgery implants (release)
Bone-disease biotech Therosteon spins out of research institute, raises funds (PDF release)
Genome-analysis toolmaker BioTrove files for $75M IPO (Edgar)
RNAi developer Tekmira acquires Protiva, ends litigation (release)
Oxford NanoLabs takes in £10M for sequencing tech – U.K. based Oxford NanoLabs, yet another startup developing high-speed genome-sequencing technology, raised £10 million in a new funding round. The company said only that its… Continue Reading
Miramar Labs gets $20M for “aesthetic” devices
Miramar Labs (no Web site), a Menlo Park, Calif., medical-device maker, raised $20.3 million in a second funding round, I’ve learned. There isn’t a huge amount of public information about the company, although it appears that the company is working on electromechanical devices of some sort for “aesthetic indications” — cosmetic surgery, in short.
Investors in the round included Split Rock Partners, Morgenthaler Partners and Domain Partners.
Life sciences briefing: Monday, Oct. 22, 2007
Featured companies: Ablynx, Avant Immunotherapeutics, BioForm Medical, Celldex Therapeutics, Genomas, High-Throughput Genomics, Orchid Cellmark, ReliaGene Technologies, SarCode, TransMolecular, VisEn Medical
UPDATED: Expanded items on SarCode, Celldex/Avant and Ablynx.
UPDATE REDUX: Added items on BioForm Medical, High-Throughput Genomics and Orchid Cellmark/ReliaGene.
San Francisco’s SarCode draws down $7M for inflammation drugs — The two-year-old startup drew down $7 million as part of a $25 million first funding round the company arranged last December, VentureWire reports (subscription required). Investors in that round included Alta… Continue Reading